Comparison between Alendronic Acid vs Denosumab
| Parameter | Alendronic Acid | Denosumab |
|---|---|---|
| Class | Bisphosphonate | RANKL inhibitor |
| Mechanism | Inhibits bone resorption | Inhibits osteoclasts |
| Onset | Gradual | Gradual |
| Monitoring | None | None |
| Dosing | Weekly/Monthly | 6 monthly injection |
| Half-life | Long | ~25 days |
| Reversal Agent | None | None |
| Bleeding Risk | Low | Low |
| Indications | Osteoporosis | Osteoporosis |
| Renal Use | Caution | Caution |
| Pregnancy Use | Avoid | Avoid |
| Drug Interactions | Few | Few |
| Adherence Sensitivity | Moderate | Moderate |
| Best Use Case | First line oral | Injection alternative |
| Cost | Low | High |
| Monitoring Burden | Low | Low |
| Clinical Flexibility | Moderate | Moderate |
| Real-world Convenience | Moderate | High |
| Overall Verdict | Established | Convenient |
| Food Interactions | None | None |